Advances in erythropoietic growth factor therapy for myelodysplastic syndromes-Reference-Cited by-同舟云学术

Advances in erythropoietic growth factor therapy for myelodysplastic syndromes

Published:2006-10-18 Issue:11 Volume:6 Page:1099-1104
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Mundle Suneel D

Publisher

Informa Healthcare

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.1517/14712598.6.11.1099

Reference27 articles.

1. MUNDLE S: Intramedullary apoptosis: a biologic hallmark of myelodysplastic syndromes. In:The Molecular and Cellular Pathology of Cancer Progression and Prognosis.Sherbet G (Ed.), Research Signpost Press, Kerala, India (2006):431-444.

2. The Myelodysplastic Syndromes: Diagnosis and Treatment

3. FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension

4. Decitabine improves patient outcomes in myelodysplastic syndromes

5. Lenalidomide: an immunomodulatory drug

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disorders of Blood Cell Production in Clinical Oncology;Abeloff's Clinical Oncology;2014

2. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents;British Journal of Haematology;2011-12-23

3. The Antioxidant Effect of Erythropoietin on Thalassemic Blood Cells;Anemia;2010

4. An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach;Cancer;2009-02-15

5. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes;Future Oncology;2007-08